Fast Neuroprotection (Fast-NPRX) for Acute Ischemic Stroke Victims: the Time for Treatment Is Now

[1]  S. Ricci,et al.  Italian guidelines on thrombolysis indications in ischaemic stroke have been revised after IST 3 trial and Cochrane Review: PROS , 2013, Internal and Emergency Medicine.

[2]  G. Costantino,et al.  Italian guidelines on thrombolysis indications in ischemic stroke have been revised after IST-3 trial and Cochrane revision: cons , 2013, Internal and Emergency Medicine.

[3]  Mary G. George,et al.  An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.

[4]  S. Kasner,et al.  Transcranial Laser Therapy and Infarct Volume , 2013, Stroke.

[5]  Adrian F Hernandez,et al.  Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. , 2013, JAMA.

[6]  Eric E. Smith,et al.  Prenotification and Other Factors Involved in Rapid tPA Administration , 2013, Current Atherosclerosis Reports.

[7]  N. Knuckey,et al.  FAST-Mag protocol with or without mild hypothermia (35°C) does not improve outcome after permanent MCAO in rats. , 2013, Magnesium Research.

[8]  Arne Voie,et al.  Prehospital stroke diagnosis and treatment in ambulances and helicopters-a concept paper. , 2013, The American journal of emergency medicine.

[9]  John H. Zhang,et al.  Early Brain Injury, an Evolving Frontier in Subarachnoid Hemorrhage Research , 2013, Translational Stroke Research.

[10]  P. Lapchak.  Recommendations and practices to optimize stroke therapy: developing effective translational research programs. , 2013, Stroke.

[11]  D. Boudreau,et al.  A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. , 2013, Annals of emergency medicine.

[12]  Eric E. Smith,et al.  Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines–Stroke Hospitals , 2013, Circulation. Cardiovascular quality and outcomes.

[13]  P. Hurn,et al.  Biological Sex and Mechanisms of Ischemic Brain Injury , 2013, Translational Stroke Research.

[14]  N. Alkayed,et al.  Mechanism of the Sex Difference in Endothelial Dysfunction after Stroke , 2013, Translational Stroke Research.

[15]  D. Liebeskind,et al.  Recommendations for Preclinical Research in Hemorrhagic Transformation , 2013, Translational Stroke Research.

[16]  M. Stenzel-Poore,et al.  Steps to Translate Preconditioning from Basic Research to the Clinic , 2013, Translational Stroke Research.

[17]  S. Lazic,et al.  A call for transparent reporting to optimize the predictive value of preclinical research , 2012, Nature.

[18]  D. J. Cook,et al.  A Translational Paradigm for the Preclinical Evaluation of the Stroke Neuroprotectant Tat-NR2B9c in Gyrencephalic Nonhuman Primates , 2012, Science Translational Medicine.

[19]  A. Buchan,et al.  Neuroprotection for Stroke: Current Status and Future Perspectives , 2012, International journal of molecular sciences.

[20]  John H. Zhang,et al.  RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research , 2012, Translational Stroke Research.

[21]  Susan Thaul,et al.  How FDA Approves Drugs and Regulates Their Safety and Effectiveness [May 18, 2012] , 2012 .

[22]  S. Doré,et al.  Translating Basic Science Research to Clinical Application: Models and Strategies for Intracerebral Hemorrhage , 2012, Front. Neur..

[23]  D. J. Cook,et al.  Nonhuman Primate Models of Stroke for Translational Neuroprotection Research , 2012, Neurotherapeutics.

[24]  G. Donnan,et al.  A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. , 2012, The New England journal of medicine.

[25]  J. Switzer,et al.  Minocycline Prevents IL-6 Increase after Acute Ischemic Stroke , 2012, Translational Stroke Research.

[26]  Shao-Hua Yang,et al.  Transient Focal Cerebral Ischemia Induces Long-term Cerebral Vasculature Dysfunction in a Rodent Experimental Stroke Model , 2012, Translational Stroke Research.

[27]  Thilo Hölscher,et al.  Transcranial Ultrasound from Diagnosis to Early Stroke Treatment – Part 2: Prehospital Neurosonography in Patients with Acute Stroke – The Regensburg Stroke Mobile Project , 2012, Cerebrovascular Diseases.

[28]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[29]  E. Peterson,et al.  A Qualitative Assessment of Practices Associated With Shorter Door-to-Needle Time for Thrombolytic Therapy in Acute Ischemic Stroke , 2011, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.

[30]  Eric E. Smith,et al.  Improving Door-to-Needle Times in Acute Ischemic Stroke: The Design and Rationale for the American Heart Association/American Stroke Association's Target Stroke Initiative , 2011, Stroke.

[31]  A. C. M. Ercolin,et al.  The use of animal models for stroke research: a review. , 2011, Comparative medicine.

[32]  P. Lapchak.  Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims , 2011, Translational Stroke Research.

[33]  A. Ergul,et al.  Neurovascular Injury in Acute Hyperglycemia and Diabetes: a Comparative Analysis in Experimental Stroke , 2011, Translational Stroke Research.

[34]  D. Hess,et al.  Minocycline Development for Acute Ischemic Stroke , 2011, Translational Stroke Research.

[35]  Adrian F Hernandez,et al.  Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke: Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes , 2011, Circulation.

[36]  F. Sharp,et al.  Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles? , 2011, Translational Stroke Research.

[37]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[38]  G. Donnan,et al.  History of Animal Models of Stroke , 2011, International Journal of Stroke.

[39]  John H. Zhang,et al.  Resolving the Negative Data Publication Dilemma in Translational Stroke Research , 2011, Translational Stroke Research.

[40]  J. Mckim,et al.  CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut , 2011, Translational Stroke Research.

[41]  Sung-Chun Tang,et al.  Pathophysiology, treatment, and animal and cellular models of human ischemic stroke , 2011, Molecular Neurodegeneration.

[42]  D. Cutler,et al.  Trends in thrombolytic use for ischemic stroke in the United States. , 2010, Journal of hospital medicine.

[43]  R. Conwit,et al.  Intercontinental Elicitation of Informed Consent for Enrollment in Stroke Research , 2010, Cerebrovascular Diseases.

[44]  J. Saver,et al.  Targeting the Brain: Neuroprotection and Neurorestoration in Ischemic Stroke , 2010, Pharmacotherapy.

[45]  Xin Zhao,et al.  The “Golden Hour” and Acute Brain Ischemia: Presenting Features and Lytic Therapy in >30 000 Patients Arriving Within 60 Minutes of Stroke Onset , 2010, Stroke.

[46]  Muzamil Ahmad,et al.  Inflammation After Stroke: Mechanisms and Therapeutic Approaches , 2010, Translational Stroke Research.

[47]  R. Vemuganti.  The MicroRNAs and Stroke: No Need to be Coded to be Counted , 2010, Translational Stroke Research.

[48]  Gregory W Albers,et al.  Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials , 2010, The Lancet.

[49]  John H. Zhang,et al.  Magnesium Sulfate Treatment Improves Outcome in Patients with Subarachnoid Hemorrhage: A Meta-analysis Study , 2010, Translational Stroke Research.

[50]  P. Lapchak.  Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development , 2010, Translational Stroke Research.

[51]  J. Grotta,et al.  Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke: Results of a Prematurely Terminated Randomized Clinical Trial , 2010, Stroke.

[52]  J. Mckim.  Building a Tiered Approach to In Vitro Predictive Toxicity Screening: A Focus on Assays with In Vivo Relevance , 2010, Combinatorial chemistry & high throughput screening.

[53]  Eng H. Lo,et al.  The Science of Stroke: Mechanisms in Search of Treatments , 2010, Neuron.

[54]  Joanna Wardlaw,et al.  Stroke treatment with alteplase given 3·0–4·5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial , 2009, The Lancet Neurology.

[55]  H. Reichmann,et al.  Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke , 2009, Stroke.

[56]  R. Conwit,et al.  Simultaneous Ring Voice-over-Internet Phone System Enables Rapid Physician Elicitation of Explicit Informed Consent in Prehospital Stroke Treatment Trials , 2009, Cerebrovascular Diseases.

[57]  R. Bordet,et al.  [Cerebral ischaemia: tomorrow's therapeutic tracks]. , 2009, Medecine sciences : M/S.

[58]  M. Lansberg,et al.  Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis , 2009, Stroke.

[59]  B. Dunn,et al.  Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. , 2009, Stroke.

[60]  Marc Fisher,et al.  Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke , 2009, Stroke.

[61]  J. Attia,et al.  Acute ischemic stroke , 2009, Neurology.

[62]  S. Savitz.  Cosmic Implications of NXY-059 , 2009, Stroke.

[63]  E. Lo,et al.  The neurovascular unit in health and disease: introduction. , 2009, Stroke.

[64]  S. Warach,et al.  Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study , 2009, The Lancet Neurology.

[65]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[66]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[67]  A. Rabinstein.  Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window , 2009 .

[68]  R. Bordet,et al.  [Cerebral ischaemia: tomorrow's therapeutic tracks]. , 2009, Medecine sciences : M/S.

[69]  Thilo Hölscher,et al.  Transcranial Ultrasound from Diagnosis to Early Stroke Treatment , 2008, Cerebrovascular Diseases.

[70]  M. Kaste,et al.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. , 2008, The New England journal of medicine.

[71]  Michael Krams,et al.  Missing Steps in the STAIR Case: A Translational Medicine Perspective on the Development of NXY-059 for Treatment of Acute Ischemic Stroke , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[72]  Hans-Christoph Diener,et al.  NXY-059 for the treatment of acute ischemic stroke. , 2007, The New England journal of medicine.

[73]  Marc Fisher,et al.  Infrared Laser Therapy for Ischemic Stroke: A New Treatment Strategy: Results of the NeuroThera Effectiveness and Safety Trial–1 (NEST-1) , 2007, Stroke.

[74]  J. Biller,et al.  Desmoteplase in the treatment of acute ischemic stroke , 2007, Expert review of neurotherapeutics.

[75]  J. Koziol.  NXY-059 for acute ischemic stroke. , 2006, The New England journal of medicine.

[76]  Steven Warach,et al.  Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset , 2006, Stroke.

[77]  G. Donnan,et al.  1,026 Experimental treatments in acute stroke , 2006, Annals of neurology.

[78]  J. Saver.  Time Is Brain—Quantified , 2006, Stroke.

[79]  A. Rabinstein.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2006 .

[80]  Joseph P Broderick,et al.  Acute Stroke Care in the US: Results from 4 Pilot Prototypes of the Paul Coverdell National Acute Stroke Registry , 2005, Stroke.

[81]  S. Warach,et al.  The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase , 2005, Stroke.

[82]  P. Gorelick,et al.  IMAGES and FAST-MAG: magnesium for acute ischaemic stroke , 2004, The Lancet Neurology.

[83]  S. Starkman,et al.  Hyperacute treatment initiation in neuroprotective agent stroke trials. , 2004, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[84]  Jeffrey L. Saver,et al.  Prehospital Neuroprotective Therapy for Acute Stroke: Results of the Field Administration of Stroke Therapy–Magnesium (FAST–MAG) Pilot Trial , 2004, Stroke.

[85]  P. Lapchak,et al.  Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits , 2004, Experimental Neurology.

[86]  M. Meadows.  The FDA's drug review process: ensuring drugs are safe and effective. , 2002, FDA consumer.

[87]  Meilin Liu,et al.  Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. , 2013, The Cochrane database of systematic reviews.

[88]  Stroke Therapy Academic Industry Roundtable.  Recommendations for standards regarding preclinical neuroprotective and restorative drug development. , 1999, Stroke.

[89]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[90]  Robert C. Wolpert,et al.  A Review of the , 1985 .